Part I: Testicular cancer - Management of early disease

Lancet Oncology

Volumn 4, Issue 12, 2003, Pages 730-737

  Jones, Robert H ^a   Vasey, Paul A ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18;

ALOPECIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR SYMPTOM; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; EARLY CANCER; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INFERTILITY; LEUKOPENIA; LYMPH NODE DISSECTION; MALE; MEDICAL DECISION MAKING; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OTOTOXICITY; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEMINOMA; TESTIS CANCER; VOMITING;

EID: 0346873053     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01278-6     Document Type: Review

References (53)

1. Chaganti RSK, Houldsworth J. Genetics and biology of adult human male germ cell tumours. Cancer Res 2000; 60: 1475-82.
2. Diekmann KP, Skakkebaek NE. Carcinoma in situ of the testis, review of biological and clinical features. Int J Cancer 1999; 83: 815-22.
3. Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of testis tumours 2nd edn. Berlin: Springer-Verlag, 1998.
4. Pugh RC (Ed). Pathology of the testis. Oxford: Blackwell Scientific, 1976.
5. Jones RH, Vasey PA. New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. Eur J Cancer 2003; 39: 147-56.
6. Horwich A. Testicular Cancer. In: Horwich A (Ed). Oncology-a multidisciplinary textbook. London: Chapman and Hall, 1995: 485-98.
7. IGCCCG. International Germ Cell Consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
8. Shakebak NE, Berthelsen JG, Muller J. Carcinoma in situ of the undescended testis. Urol Clin North Am. 1982; 9: 377-85.
9. Manning M, Junnermann KP, Alken P. Decrease in testosterone blood concentrations after testicular sperm extraction for intracytoplasmic sperm injection in azoospermic men. Lancet 1998; 352: 37-43.
10. Petersen P, Giwercman A, Daugaard G, et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol 2002; 20: 1537-43.
11. Krege S, Souchon R, Schmoll HJ. German Testicular Cancer Study Group. Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur Urol 2001; 40: 372-91.
12. G Read, Stenning SP, Cullen MH, et al., Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992; 10: 1762-68.
13. Sogani PC, Perrotti M, Herr HW, et al. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998; 159: 855-62.
14. Alexandre J, Fizazi K, Mahe C, et al. Stage I nonseminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 2001; 37: 576-82.
15. Heidenreich A, Sesterhenn IA, Mostofi FK, et al. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 1998; 83: 1002-11.
16. Leibovitch I, Foster RS, Kopecky KK, et al., Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitative immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 1998; 16: 261-68.
17. Pont J, Holtl W, Kosak D, et al. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. J Clin Oncol 1990; 8: 16-23.
18. Sweeney CJ, Hermans BP, Heilman DK, et al. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. J Clin Oncol 2000; 18: 358-62.
19. Albers P, Ulbright TM, Albers J, et al. Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. J Urol 1996; 155: 579-86,
20. Albers P, Siener R, Kliesch S. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the german testicular cancer study group trial. J Clin Oncol 2003; 21: 1505-12.
21. Rabbani F, Sheinfeld J, Farivar-Mohseni H, et al. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol. 2001; 19: 2020-25.
22. Clinical Oncology Information Network (COIN). Guidelines on the management of adult testicular cancer. Clin Oncol 2000; 12 (Suppl): S173-210.
23. Cullen M, Stenning S, Parkinson M, et al. Short course adjuvant chemotherapy in high risk stage I nonseminomatous germ cell tumours of the testis (NSGCTT): an MRC(UK) study report. J Clin Oncol. 1996; 14: 1106-11.
24. Bohlen D, Borner M, Sonntag RW, et al Long-term results following adjuvant chemotherapy in patients with clinical stage 1 testicular nonseminomatous malignant germ cell tumours with high risk factors. J Urol 1999; 161: 1148-51.
25. Oliver RTD, Raja M, Ong J, Gallagher C. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I cancer patients. J Urol 1992; 148: 1453-60.
26. Kollmannsberger C, Kuzcyk M, Mayer F, et al. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 1999 17: 275-81.
27. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513-23.
28. Siener R, Albers P, Kliesch S, et al. Fertility in patients with stage I non-seminomatous germ-cell tumors (NSGCT): analysis of the German prospective multicenter trial. Proc Am Soc Clin Oncol 2002; 21: (abstr 752).
29. Dearnaley D, Fossa S, Kaye S, et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high risk clinical stage I (HRCS1) non-seminomatous germ cell tumours (NSGCT): a Medical Research Council (MRC) pilot study. Proc Am Soc Clin Oncol 1998; 17: (abstr 309).
30. Schefer H, Mattmann S, Borner M, et al. Single course adjuvant bleomycin, etoposide and cisplatin (BEP) for high risk stage I non-seminomatous germ cell tumors (NSGCT) Proc Am Soc Clin Oncol 2000; 19: (abstr 340).
31. Donohue JP, Thornhill JA, Foster RS, et al. Primary retroperitoneal lymph node dissection in clinical stage A nonseminomatous germ cell testis cancer: a review ofthe Indiana University experience (1965-1989). Br J Urol 1993; 71: 326-35.
32. Foster R, Donohue JP. Retroperitoneal lymph node dissection for the management of clinical stage nonseminoma. J Urol 2000; 163: 1788-92.
33. Gerl A, Clemm C, Schmeller N, et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997; 8: 41-47.
34. Baniel, J, Foster, R, Einhorn, L, Donohue, J. Late relapse of clinical stage I testicular cancer. J Urol. 1995; 154: 1370-72.
35. Heidenreich A, Albers P, Kohrmann KU, et al. Complications of primary nerve sparing retroperitoneal lymphadenectomy in clinical stage I nonseminomatous testis cancer. Eur Urol 2002; 1: 36A.
36. Weissbach L, Boedefeld EA, Horstmann-Dubral B. Surgical treatment of stage-I non-seminomatous germ cell testis tumor. Eur Urol 1990; 17: 97-103.
37. Roeleveld TA, Horenblas S, Meinhardt W, et al. Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J Urol 2001; 166: 2166-70.
38. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 1999; 17: 1146-53.
39. Fossa SD, Jones WG, Stenning SP. Quality of life (QL) after radiotherapy (RT) for stage I seminoma: results from a randomised trial of two RT schedules (MRC TE18). Proc Am Soc Clin Oncol 2002; 21: 750a.
40. Horwich A, Oliver R, Wilkinson P, et al. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br J Cancer 2000; 83: 1623-29.
41. Clemm C, Bokemeyer C, Gerl A, et al. Randomized trial comparing cisplatin/etoposide/ifosfamide with carboplatin monochemotherapy in patients with advanced metastatic seminoma Proc Am Soc Clin Oncol 2000; 19: (abstr 326).
42. Steiner H, Holtl L, Wirtenberger W, et al. Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology 2002; 60: 324-28.
43. Reiter WJ, Brodowicz T, Alavi S, et al. Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 2001; 19: 101-04.
44. Dieckmann KP, Bruggeboes B, Pichlmeier U, et al. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 2000; 55: 102-06.
45. Warde P, Gospodarowicz MK, Panzaralla T, et al. Long term outcome and cost in the management of stage I testicular seminoma. Can J Urol 2000; 7: 967-72.
46. von der Maase H, Specht L, Jacobsen GK, et al., Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993; 14: 1931-34.
47. Peckham MJ, Hamilton CR, Horwich A, Hendry WE. Surveillance after orchidectomy for stage I seminoma of the testis. Br J Urol 1987; 59: 343-47.
48. Duchesne GM, Horwich A, Dearnaley DP, et al. Orchidectomy alone for stage I seminoma of the testis. Cancer 1990; 65: 1115-18.
49. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002; 21: 4448-52.
50. Cremerius U, Effert P, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med 1998; 39: 815-22.
51. Spermon JR, de Geus-Oei LF, Kiemeney LALM, et al. The role of 18FDG-PET in initial staging and restaging after chemotherapy for testicular germ cell tumours. BJU Int 2002; 89: 549-56.
52. Albers P, Bender H, Yilmaz H, et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999; 53: 808-11.
53. Hain SF, O'Doherty MJ, Timothy AR, et al. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000; 27: 590-94.